Commentary finds randomized controlled trials failing to enhance PTSD care, highlighting the need for transparent clinical data.
In my view, randomized controlled trials for posttraumatic stress disorder (PTSD) have reached a point of diminishing returns: There is equipoise among bona fide manualized short‐term psychotherapies, dropout is pervasive, most patients do not make clinically significant gains, and no efficient pathway exists for discovering how to personalize care or prevent nonresponse. Progress now depends on leveraging real‐world clinical experiences and outcomes as engines of learning. Observational outcome data are indispensable for this purpose but are often misinterpreted as generalizable evidence of effectiveness. In response to Lancaster et al. (2025), this commentary outlines principles and checklist items for transparent, hypothesis‐generating reporting that can transform routine clinical data from descriptive snapshots of performance into a scalable foundation for discovery, quality improvement, and advancement in PTSD care.
No takes yet. Share an insight, caveat, or question.
Brett T. Litz (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: